Drug Safety

, Volume 24, Issue 8, pp 599–606 | Cite as

Drug-Induced Angioedema without Urticaria

Incidence, Prevention and Management
Review Article

Abstract

Angioedema without urticaria is a clinical syndrome characterised by self-limiting local swellings involving the deeper cutaneous and mucosa tissue layers. Most occurrences of angioedema respond to treatment with a histamine H1 receptor blocker (antihistamine) because they are an allergic or parallergic reaction. A small number of cases do not respond to antihistamine treatment. Such cases tend to occur in patients with deficiency or dysfunction of the inhibitor of the first component of the complement (C1-INH), but more rarely can occur in patients with other conditions and as an adverse drug reaction.

Angioedema is well documented in patients taking ACE inhibitors. Considering that 35 to 40 million patients are treated worldwide with ACE inhibitors, this drug class could account for several hundred deaths per year from laryngeal oedema. ACE inhibitors certainly do not mediate angioedema through an allergic or idiosyncratic reaction. For this reason the relationship with this drug is often missed and consequently quite underestimated. Rare instances of angioedema have also been reported with angiotensin II receptor antagonists. This adverse effect seems to occur less frequently with angiotensin II receptor antagonists than with ACE inhibitors. However, we do not know whether this adverse effect has the same mechanism with the 2 classes of medications. Some cases of severe angioedema have been recently reported after treatment with fibrinolytic agents. Scattered reports suggest the possibility of angioedema associated with the use of estrogens, antihypertensive drugs other than ACE inhibitors, and psychotropic drugs. Angioedema can also occur with nonsteroidal anti-inflammatory drugs.

Prevention of angioedema relies first on the patient history. Estrogen and ACE inhibitors should be avoided in a patient with congenital or acquired C1-INH deficiency. In the case of ACE inhibitors, the appearance of angioedema following long term treatment does not lessen the probability that such an agent could be the cause. The most important action to take in a patient with suspected drug-induced angioedema is to discontinue the pharmacological agent. Epinephrine (adrenaline), diphenydramine and intravenous methylprednisolone have been proposed for the medical management of airway obstruction, but so far no controlled studies have demonstrated their efficacy. If the acute airway obstruction leads to life-threatening respiratory compromise an emergency cricothyroidotomy must be performed.

References

  1. 1.
    Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356(9237): 1255–9PubMedCrossRefGoogle Scholar
  2. 2.
    World Health Organization. International drug monitoring: the role of national centres: report of a WHO meeting. World Health Organ Tech Rep Ser 1972; 498: 1–25Google Scholar
  3. 3.
    Friedmann PS. Assessment of urticaria and angio-oedema. Clin Exp Allergy 1999; 29Suppl. 3: 109–12PubMedCrossRefGoogle Scholar
  4. 4.
    Davis AE. C1 inhibitor and hereditary angioneurotic edema. Annu Rev Immunol 1988; 6: 595–628PubMedCrossRefGoogle Scholar
  5. 5.
    Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992; 71(4): 206–15Google Scholar
  6. 6.
    Binkley KE, Davis III A. Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. J Allergy Clin Immunol 2000; 106(3 Pt 1): 546–50PubMedCrossRefGoogle Scholar
  7. 7.
    Bork K, Barnstedt SE, Koch P, et al. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000; 356(9225): 213–7PubMedCrossRefGoogle Scholar
  8. 8.
    Warin RP, Cunliffe WJ, Greaves MW, et al. Recurrent angioedema: familial and oestrogen-induced. Br J Dermatol 1986; 115(6): 731–4PubMedCrossRefGoogle Scholar
  9. 9.
    Cicardi M, Bergamaschini L, Zingale LC et al. Idiopathic nonhistaminergic angioedema. Am J Med 1999; 106(6): 650–4PubMedCrossRefGoogle Scholar
  10. 10.
    Bircher AJ. Drug-induced urticaria and angioedema caused by non-IgE mediated pathomechanisms. Eur J Dermatol 1999; 9(8): 657–63PubMedGoogle Scholar
  11. 11.
    Vleeming W, van Amsterdam JG, Stricker BH, et al. ACE inhibitor-induced angioedema: incidence, prevention and management. Drug Saf 1998; 18(3): 171–88PubMedCrossRefGoogle Scholar
  12. 12.
    Grossman E, Messerli FH, Neutel JM. Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors? Arch Intern Med 2000; 160(13): 1905–11PubMedCrossRefGoogle Scholar
  13. 13.
    Messerli FH, Nussberger J. Vasopeptidase inhibition and angiooedema. Lancet 2000; 356(9230): 608–9PubMedCrossRefGoogle Scholar
  14. 14.
    Agostoni A, Cicardi M, Cugno M, et al. Angioedema due to angiotensin-converting enzyme inhibitors. Immunopharmacology 1999; 44(1-2): 21–5PubMedCrossRefGoogle Scholar
  15. 15.
    Byrne TJ, Douglas DD, Landis ME, et al. Isolated visceral angioedema: an underdiagnosed complication of ACE inhibitors? Mayo Clin Proc 2000; 75: 1201–4PubMedCrossRefGoogle Scholar
  16. 16.
    Pellacani A, Brunner HR, Nussberger J. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. Clin Sci (Colch) 1994; 87(5): 567–74Google Scholar
  17. 17.
    Nussberger J, Cugno M, Amstutz C, et al. Plasma bradykinin in angio-oedema. Lancet 1998; 351(9117): 1693–7PubMedCrossRefGoogle Scholar
  18. 18.
    Sigler C, Annis K, Cooper K, et al. Examination of baseline levels of carboxypeptidase N and complement components as potential predictors of angioedema associated with the use of an angiotensin-converting enzyme inhibitor. Arch Dermatol 1997; 133(8): 972–5PubMedCrossRefGoogle Scholar
  19. 19.
    Marcic BM, Erdös EG. Protein kinase C and phosphatase inhibitors block the ability of angiotensin I-converting enzyme inhibitors to resensitize the receptor to bradykinin without altering the primary effects of bradykinin. J Pharmacol Exp Ther 2000; 294(2): 605–12PubMedGoogle Scholar
  20. 20.
    Blais Jr C, Rouleau JL, Brown NJ, et al. Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. Immunopharmacology 1999; 43(2-3): 293–302PubMedCrossRefGoogle Scholar
  21. 21.
    Brown NJ, Ray WA, Snowden M, et al. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther 1996; 60(1): 8–13PubMedCrossRefGoogle Scholar
  22. 22.
    Ajayi AA, Adigun AQ. Angioedema and cough in Nigerian patients receiving ACE inhibitors [letter]. Br J Clin Pharmacol 2000; 50(1): 81–2PubMedCrossRefGoogle Scholar
  23. 23.
    Gruchalla RS. Clinical assessment of drug-induced disease. Lancet 2000; 356(9240): 1505–11PubMedCrossRefGoogle Scholar
  24. 24.
    Gabb GM, Ryan P, Wing LM, et al. Epidemiological study of angioedema and ACE inhibitors. Aust N Z J Med 1996; 26(6): 777–82PubMedCrossRefGoogle Scholar
  25. 25.
    Cha YJ, Pearson VE. Angioedema due to losartan. Ann Pharmacother 1999; 33(9): 936–8PubMedCrossRefGoogle Scholar
  26. 26.
    Rivera JO. Losartan-induced angioedema. Ann Pharmacother 1999; 33(9): 933–5PubMedCrossRefGoogle Scholar
  27. 27.
    Rupprecht R, Vente C, Grafe A, et al. Angioedema due to losartan. Allergy 1999; 54(1): 81–2PubMedCrossRefGoogle Scholar
  28. 28.
    de Paz S, Martin AB, Iglesias A, et al. Angioedema-urticaria caused by angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists. Med Clin (Barc) 1999; 113(19): 759Google Scholar
  29. 29.
    Frye CB, Pettigrew TJ. Angioedema and photosensitive rash induced by valsartan. Pharmacotherapy 1998; 18(4): 866–8PubMedGoogle Scholar
  30. 30.
    Sharma PK, Yium JJ. Angioedema associated with angiotensin II receptor antagonist losartan. South Med J 1997; 90(5): 552–3PubMedCrossRefGoogle Scholar
  31. 31.
    Boxer M. Accupril- and Cozaar-induced angioedema in the same patient. J Allergy Clin Immunol 1996; 98(2): 471PubMedCrossRefGoogle Scholar
  32. 32.
    van Rijnsoever EW, Kwee-Zuiderwijk WJ, Feenstra J. Angioneurotic edema attributed to the use of losartan. Arch Intern Med 1998; 158(18): 2063–5PubMedCrossRefGoogle Scholar
  33. 33.
    Schuster C, Reinhart WH, Hartman K, et al. Angioedema induced by ACE inhibitors and angiotensin II-receptor antagonists: analysis of 98 cases. Schweiz Med Wochenschr 1999; 129: 362–9PubMedGoogle Scholar
  34. 34.
    Fuchs SA, Koopmans RP, Guchelaar HI, et al. Are angiotensin II receptor antagonists safe in patients with previous angiotensin-converting enzyme inhibitor-induced angioedema? Hypertension 2001; 37(1): U11CrossRefGoogle Scholar
  35. 35.
    Sato M, Engelman RM, Otani H, et al. Myocardial protection by preconditioning of heart with losartan, an angiotensin II type 1-receptor blocker: implication of bradykinin-dependent and bradykinin-independent mechanisms. Circulation 2000; 102(19 Suppl. 3): III346–51PubMedGoogle Scholar
  36. 36.
    Liu YH, Yang XP, Sharov VG, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997; 99(8): 1926–35PubMedCrossRefGoogle Scholar
  37. 37.
    Rudolf J, Grond M, Schmulling S, et al. Orolingual angioneurotic edema following therapy of acute ischemic stroke with alteplase. Neurology 2000; 55(4): 599–600PubMedCrossRefGoogle Scholar
  38. 38.
    Cooper JP, Quarry DP, Beale DJ, et al. Life-threatening, localized angio-oedema associated with streptokinase. Postgrad Med J 1994; 70(826): 592–3PubMedCrossRefGoogle Scholar
  39. 39.
    Pancioli A, Brott T, Donaldson V, et al. Asymmetric angioneurotic edema associated with thrombolysis for acute stroke. Ann Emerg Med 1997; 30(2): 227–9PubMedCrossRefGoogle Scholar
  40. 40.
    Walls RM, Pollack Jr CV. Successful cricothyrotomy after thrombolytic therapy for acute myocardial infarction: a report of two cases. Ann Emerg Med 2000; 35(2): 188–91PubMedCrossRefGoogle Scholar
  41. 41.
    Hill MD, Barber PA, Takahashi J, et al. Anaphylactoid reactions and angioedema during alteplase treatment of acute ischemic stroke. CMAJ 2000; 162(9): 1281–4PubMedGoogle Scholar
  42. 42.
    Francis CW, Brenner B, Leddy JP, et al. Angioedema during therapy with recombinant tissue plasminogen activator. Br J Haematol 1991; 77(4): 562–3PubMedGoogle Scholar
  43. 43.
    Caliezi C, Wuillemin WA, Zeerleder S, et al. C1-esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev 2000; 52(1): 91–112PubMedGoogle Scholar
  44. 44.
    Agostoni A, Gardinali M, Frangi D, et al. Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction: a comparison between streptokinase and recombinant tissue-type plasminogen activator. Circulation 1994; 90(6): 2666–70PubMedCrossRefGoogle Scholar
  45. 45.
    McGlinchey PG, McCluskey DR. Hereditary angioedema precipitated by estrogen replacement therapy in a menopausal woman. Am J Med Sci 2000; 320(3): 212–3PubMedCrossRefGoogle Scholar
  46. 46.
    Pichler WJ, Lehner R, Spath PJ. Recurrent angioedema associated with hypogonadism or anti-androgen therapy. Ann Allergy 1989; 63(4): 301–5PubMedGoogle Scholar
  47. 47.
    Ponard D, Pernollet M, Richard-Lallemand M-A, et al. Acquired angioedema associated with anti-androgen therapy in a young woman. Exp Clin Immunogenet 1997; 14: 101Google Scholar
  48. 48.
    Fujimoto J, Hori M, Itoh T, et al. Danazol decreases transcription of estrogen receptor gene in human monocytes. Gen Pharmacol 1995; 26: 507–16PubMedCrossRefGoogle Scholar
  49. 49.
    Settipane GA. Adverse reactions of aspirin and related drugs. Arch Intern Med 1981; 141(3 Spec. No): 328–32PubMedCrossRefGoogle Scholar
  50. 50.
    Asero R. Leukotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria. Ann Allergy Asthma Immunol 2000; 85(2): 156–7PubMedCrossRefGoogle Scholar
  51. 51.
    Bavbek S, Celik G, Ediger D, et al. The use of nimesulide in patients with acetylsalicylic acid and nonsteroidal anti-inflammatory drug intolerance. J Asthma 1999; 36(8): 657–63PubMedCrossRefGoogle Scholar
  52. 52.
    Krikorian RK, Quick A, Tal A. Angioedema following the intravenous administration of metoprolol. Chest 1994; 106(6): 1922–3PubMedCrossRefGoogle Scholar
  53. 53.
    Sauve L, Gras-Champel V, Decocq G, et al. Angioedema associated with the use of dihydropyridines [letter]. Therapie 1999; 54(1): 64–5PubMedGoogle Scholar
  54. 54.
    Burches E, Garcia-Verdegay F, Ferrer M, et al. Amiodarone-induced angioedema. Allergy 2000; 55: 1199–200PubMedCrossRefGoogle Scholar
  55. 55.
    Cooney C, Nagy A. Angio-oedema associated with risperidone. BMJ 1995; 311(7014): 1204PubMedCrossRefGoogle Scholar
  56. 56.
    Mithani H, Hurwitz TA. Paroxetine-induced angioedema and tongue swelling. J Clin Psychiatry 1996; 57(10): 486PubMedCrossRefGoogle Scholar
  57. 57.
    Kimyai-Asadi A, Harris JC, Nousari HC. Critical overview: adverse cutaneous reactions to psychotropic medications. J Clin Psychiatry 1999; 60(10): 714–25PubMedCrossRefGoogle Scholar
  58. 58.
    Schaefer OP, Gore JM. Aspirin sensitivity: the role for aspirin challenge and desensitization in postmyocardial infarction patients. Cardiology 1999; 91(1): 8–13PubMedCrossRefGoogle Scholar
  59. 59.
    Dominguez Ortega J, Robledo T, Martinez-Cocera C, et al. Desensitization to azathioprine. J Investig Allergol Clin Immunol 1999; 9(5): 337–8PubMedGoogle Scholar
  60. 60.
    McHaourab A, Sarantopoulos C, Stowe DF. Airway obstruction due to late-onset angioneurotic edema from angiotensin-converting enzyme inhibition. Can J Anaesth 1999; 46(10): 975–8PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  1. 1.Department of Internal Medicine, IRCCS Milan Maggiore HospitalUniversity of MilanMilanItaly

Personalised recommendations